Typhonium: A Comprehensive Reference
1. Identity, Taxonomy, and Nomenclature
Botanical Classification
Typhonium flagelliforme is a species of flowering plant in the family Araceae. The genus Typhonium belongs to the order Alismatales and comprises a group of herbaceous monocots distributed across the Old World tropics. The genus Typhonium comprises about 40 species distributed widely in tropical and subtropical Asia and extends southward to Australia.
Historically, the species was first described under the name Arum flagelliforme by George Loddiges in the Botanical Cabinet in 1820, based on material likely from Southeast Asia. It was later transferred to the genus Typhonium by Carl Ludwig Blume in Rumphia in 1837, reflecting advancements in aroid taxonomy that recognized the distinct generic boundaries within Araceae.
The full accepted scientific name is Typhonium flagelliforme (G.Lodd.) Blume. The species has accumulated numerous synonyms in the literature, including Typhonium hastiferum Miq., Typhonium incurvatum Blatt. & McCann, Typhonium reinwardtianum de Vriese & Miq., and Typhonium sylvaticum Voigt, all now subsumed under the accepted name. Taxonomic revisions have also clarified that what was long called T. divaricatum in the Southeast Asian medicinal-plant literature is now synonymised under T. flagelliforme.
Closely Related Medicinal Species
Several other Typhonium species have independent or overlapping medicinal histories and are frequently discussed alongside T. flagelliforme in the scientific literature:
- Typhonium giganteum Engl. — the source of the classical Chinese herbal medicine Bai Fu Zi (Yu Bai Fu; Rhizoma Typhonii). The dry tuber of perennial herbaceous plant Typhonium giganteum Engl. of family Araceae, sourced from Henan, Gansu, and Hubei provinces in China.
- Typhonium blumei Nicolson & Sivadasan (= T. divaricatum sensu some authors) — a wildly growing weed in Taiwan, known in Chinese as Tu-Ban-Xia (TB).
- Typhonium roxburghii Schott — usually not distinguished from Typhonium blumei, and commonly used interchangeably.
- Typhonium trilobatum — another folk medicinal species of South and Southeast Asia, included in the same critical revision of the genus.
Several Typhonium species are often confused; four of them, namely Typhonium blumei (= Typhonium divaricatum), Typhonium roxburghii, Typhonium flagelliforme, and Typhonium trilobatum, were critically revised by Nicolson and Sivadasan (1981). This taxonomic confusion has been a persistent challenge in interpreting the ethnobotanical and pharmacological literature, and care must be taken when comparing studies that use different species names.
Common Names
In Malay and Indonesian, T. flagelliforme is known as "keladi tikus," where "keladi" refers to taro-like plants in the Araceae family and "tikus" means rat or mouse; the English common name "rodent tuber" similarly emphasizes this rodent-like shape of the underground tuber. In Tagalog (Philippines), it is called "gabi ng daga" or "gabi-daga," translating to "rat taro," again due to the tuber's resemblance to a rat. For T. giganteum, the classical Chinese medicinal name is Bai Fu Zi (白附子) or Yu Bai Fu. T. blumei/T. divaricatum is called Tu Ban Xia (土半夏) in China and Taiwan.
Morphology and Natural Distribution
T. flagelliforme is a small herb of up to 40 cm tall with simple leaves borne on a long stalk; the inflorescence is made up of an elongated flowering spike referred to as a spadix, enclosed by a bract-like spathe, the base of which is expanded into a pouch enclosing the flowers.
Typhonium flagelliforme is native to China (Guangdong, Guangxi, Yunnan), Bangladesh, Bhutan, Cambodia, India, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, Sri Lanka, Thailand, New Guinea, and Australia (Queensland, Northern Territory). T. flagelliforme is assessed as Least Concern (LC) on the IUCN Red List as of 2011, due to its extensive distribution across tropical and subtropical regions from India and Sri Lanka to southern China, Indochina, the Malay Peninsula, the Philippines, Indonesia, New Guinea, and northern Australia, coupled with no identified major threats at a global scale.
In contrast, Typhonium divaricatum (a name variably applied in the literature) belonging to the family Araceae is reported as an endangered species by the International Union for Conservation of Nature (IUCN).
Common Preparations and Dosage Forms
The plant can be used as a whole, starting from the root, tuber, and leaves. In traditional practice and in scientific studies, the plant material has been prepared as:
- Fresh juice / aqueous extract of whole plant or leaves, administered orally.
- Ethanol, methanol, and dichloromethane (DCM) extracts of tuber and/or leaf, used extensively in laboratory research.
- Hexane fraction of the tuber, used in cytotoxicity studies.
- Processed dried tuber (for T. giganteum), processed with alum and ginger juice prior to internal administration in traditional Chinese medicine, to reduce toxicity.
- A common folk method involves consuming a liquid extract of the whole plant mixed with honey three times daily.
- Commercial herbal supplement capsules and tablets containing dried or extracted plant material have been sold in Malaysia, Indonesia, and Singapore since the late 1990s.
2. Traditional and Historical Use
Southeast Asian Traditions
Typhonium flagelliforme (Araceae) is a medicinal herb which is endowed with curative properties against a variety of illness including injuries, oedema, coughs, pulmonary ailments, bleeding, and cancer.
T. flagelliforme is used in traditional medicine in Peninsular Malaysia and Singapore for treating different types of malignancy. The herb is used in traditional medicine in Singapore and Peninsular Malaysia for the treatment of various forms of malignancy; the plant came into prominence in the 1990s when a general practitioner in Malaysia successfully treated a number of cancer patients with the herb.
In Malay culture, Typhonium flagelliforme, known locally as keladi tikus or "rat taro," is recognized for its role in traditional healing. Ethnobotanically, T. flagelliforme is wild-harvested across Indonesia and Malaysia for local markets, where demand surged in the late 1990s and 2000s due to its incorporation into herbal supplements.
The plant grows readily in soft, damp, shady areas. It is now grown in household gardens in Malaysia and Singapore for its medicinal value.
Traditional Chinese Medicine (TCM)
T. divaricatum / T. flagelliforme is a traditional Chinese medicinal herb and has anti-inflammation, anti-viral, and anti-cancerous properties according to traditional classification.
The species T. giganteum occupies a formal and historically documented position in classical Chinese materia medica under the name Bai Fu Zi (白附子). It is classified as pungent, warm, and toxic; it enters the liver meridian; and its classical actions are described as: dispel wind-phlegm, dry damp-phlegm, stop spasms, alleviate pain, relieve toxicity and dissipate nodulation.
The classical TCM indications for Bai Fu Zi (T. giganteum) include:
- Apoplexy due to excessive phlegm accumulation, convulsions, epilepsy, and tetanus; for deviated mouth and eyes of stroke, it is usually combined with wind-extinguishing and collateral-dredging herbs such as Quan Xie and Jiang Can.
- For excessive wind-phlegm accumulation and clonic convulsion of epilepsy, it is combined with Ban Xia and Tian Nan Xing in order to enhance the actions of dispelling wind, drying dampness, and resolving phlegm.
- Dispelling wind-dampness and relieving arthralgia; it is indicated for wind-cold-damp arthralgia, aching pain, and dysfunction of flexion and extension of joints.
- Headache due to phlegm-induced syncope and vertigo; for wind migraine, it is combined with Bai Zhi to enhance the actions of extinguishing wind and alleviating pain.
- Eliminating toxicity and dissipating nodulation for scrofula, snake bites, and other nodules due to phlegm and toxicity; usually used topically for these conditions.
T. giganteum is a traditional Chinese medicine used as part of various formulas to treat respiratory diseases, stroke, and epilepsy, and is nowadays applied in cancer treatment.
Taiwanese Folk Medicine (T. blumei / Tu Ban Xia)
Typhonium blumei (= T. divaricatum; Tu-Ban-Xia) was first reported as a folk medicine in 1924 for the treatment of various diseases; it is used alone as a treatment for coughing, swelling, snake bites, and bruises; in addition, it is used to treat cancers such as leukemia, skin cancer, and liver cancer.
Despite the long history of use in folk medicine, scientific reports on the secondary metabolites content and bioactivity of T. blumei are scarce.
Ayurvedic and Unani Traditions
T. flagelliforme, belonging to the Araceae family, is a small to moderately sized perennial herb valued in Ayurveda and Unani systems of medicine; the rhizome is used in these traditions.
Processing Practices
The plant is highly irritant to skin and mucous membrane, thus care should be taken during its preparation for use. In traditional Chinese medicine, the tuber of T. giganteum is processed with alum and ginger juice to reduce its inherent toxicity before internal administration — a practice consistent with classical detoxification (paozhi) methods applied to other members of the Araceae family.
3. Key Phytochemical Constituents
The phytochemistry of the genus Typhonium has been characterized in a series of isolation and spectroscopic studies. The most comprehensively profiled species are T. flagelliforme, T. blumei, T. divaricatum, and T. giganteum.
Until now, several groups of compounds — namely amino acids, cinnamic acid, fatty acids, glycerol derivatives and cerebrosides, flavonoids, hydantoins, lignin monomers, nucleobases, pheophorbides, phthalate, terpenes and steroids, and vitamins — have been isolated and characterized from Typhonium.
Major Compound Classes
- Pheophorbides (chlorophyll degradation products):
Four pheophorbide-related compounds — pheophorbide-a, pheophorbide-a', pyropheophorbide-a, and methyl pyropheophorbide-a — were identified in the most antiproliferatively active fraction (D/F19) of T. flagelliforme. These are considered among the most pharmacologically significant antiproliferative constituents of the plant.
- Fatty acids and glycerol derivatives:
The hexane fraction of T. flagelliforme contains methyl esters of hexadecanoic acid, octadecanoic acid, 9-octadecenoic acid, and 9,12-octadecadienoic acid, as well as several common aliphatics. GC-MS analysis revealed that the most active DCM fraction (DCM/F7) from the tuber contains linoleic acid, hexadecanoic acid, and 9-hexadecanoic acid.
Phytochemical study on Typhonium blumei yielded four oxygenated fatty acids: 12R-hydroxyoctadec-9Z,13E-dienoic acid methyl ester, 10R-hydroxyoctadec-8E,12Z-dienoic acid methyl ester, 9R-hydroxy-10E-octadecenoic acid methyl ester, and 12R*-hydroxy-10E-octadecenoic acid methyl ester.
- Cerebrosides:
From the root tuber of T. flagelliforme, four compounds were identified: a cerebroside (1-O-beta-glucopyranosyl-2-[(2-hydroxyloctadecanoyl) amido]-4,8-octadecadiene-1,3-diol), coniferin, beta-sitosterol, and beta-daucosterol; a cerebroside with significant antihepatotoxic activity and a phenylpropanoid glycoside were isolated for the first time.
- Flavonoids:
The phytochemical compounds of T. flagelliforme include flavonoids, coumaric acid, and other polyphenol compounds; these compounds exhibit a wide range of pharmacological activities including antioxidant, anti-inflammatory, and anti-cancer effects. Specific flavonoids identified include flavonols such as kaempferol 3-O-rutinoside, kaempferol, and kaempferol 3-O-(6"-acetyl-galactoside)-7-O-rhamnoside. The flavone glycosides vitexin and isovitexin have also been reported from the leaves.
- Sterols and triterpenoids:
Beta-sitosterol and beta-daucosterol are among the sterols characterized. Phytochemical screening has revealed the presence of flavonoids, saponins, steroids, and triterpenoids; n-hexane extracts primarily contained steroid/triterpenoid compounds.
- Lectins:
A mannose-binding lectin gene and a mannose-binding lectin possessing antiviral activity were isolated from T. blumei / T. divaricatum.
- Hydantoins, nucleobases, and lignin monomers: Hydantoin derivatives (compounds 36–38 in the systematic review numbering) and various nucleobases (compounds 45–48) have been characterized, along with lignin monomers. These were among the 61 compounds systematically catalogued from across the genus.
- Unique fatty acid derivative:
The unique methyl ester of 13-phenyltridecanoic acid was isolated from the hexane fraction of T. flagelliforme and positively identified using spectroscopic methods.
- Stigmasterol and derivatives:
In a recent in silico and in vitro study, stigmasterol and 7α-hydroxyl stigmasterol were analyzed by molecular docking and molecular dynamics simulation, and found to act as competitive regulators with high affinity for the Farnesoid X receptor (FXR).
- Calcium oxalate raphides:
The dried stem tubers of Typhonium flagelliforme from the Araceae family are used as Chinese medicines; they have been reported to have a strong irritative effect on mucosa; previous studies have indicated that the pure raphides of calcium oxalate contained in the stem tubers are responsible for this strong irritation.
4. Mechanisms of Action
Apoptosis Induction (Pro-Apoptotic Pathway)
Phytochemicals isolated from Typhonium were investigated for their anticancer properties; results confirmed promising growth inhibitory effects and anticancer activities against human lung, breast, prostate, and colon cancer cells; and the anticancer activity of these compounds appears to be mediated through the induction of apoptotic cell death.
The apoptotic pathway has been characterized in several in vitro models. An increase in caspase-3 and -9 was found in CEMss cells treated with T. flagelliforme extract; immunoblot analysis showed that PARP (a substrate for caspase-3) was activated and cytochrome c from mitochondria was released into the cytosol, indicating that apoptosis took place in the mitochondrial-dependent pathway; Bcl-2 decreased after cells were treated with the extract.
This study also demonstrated that the cell cycle halted its progression significantly at the G0/G1 phase (p<0.05).
Cytological observations showed chromatin condensation, cell shrinkage, abnormalities of cristae, membrane blebbing, cytoplasmic extrusions, and formation of apoptotic bodies.
Anti-Tumour Marker Suppression
The expression of p21 protein was increased after treatment with T. flagelliforme extract, while the expressions of tyrosine kinase, Ki67, HER2/neu, telomerase, and COX-2 were decreased, implying T. flagelliforme could inhibit tumor growth and development.
Anti-Inflammatory Mechanisms
Typhonium blumei (Araceae) is a traditional Chinese medicinal herb possessing detumescent, detoxifying, and anti-inflammatory activities. Research on the anti-allergic properties of T. blumei showed inhibition of mast cell degranulation: the anti-allergic activity of nonpolar fractions was assessed by A23187- and antigen-induced degranulation assays using RBL-2H3 mast cells; several molecular targets were investigated including FcεRI receptor expression by flow cytometry and calcium influx.
Antiviral Lectins
A mannose-binding lectin possessing antiviral activity was isolated from T. blumei. Mannose-binding lectins are a known class of plant proteins with established antiviral properties in in vitro systems, acting by binding to viral surface glycoproteins.
Cell Cycle Arrest
In vitro findings with methanolic extract of T. flagelliforme demonstrated induction of apoptosis in different cell lines at low concentrations; cell cycle arrest by induction of cellular stress at the G2/M phase was also observed in SCC-225 cells.
Anti-Angiogenic Activity
A synergistic effect on antiproliferation and antiangiogenesis activities was observed in the combination of T. flagelliforme and canine interferons (natural and recombinant), which could be developed as another alternative approach in cancer treatments.
5. Scientific Evidence by Area of Use
5a. Oncology / Anticancer Activity
Evidence type: Predominantly in vitro and animal (preclinical); no completed published human clinical trials identified.
A 2023 systematic review published in the Journal of Traditional Chinese Medical Sciences assessed the preclinical anticancer evidence comprehensively. The review aimed to assess the potential of Typhonium flagelliforme as an anticancer agent; seven databases (Scopus, PubMed, Web of Science, ScienceDirect, LILACS, EBSCO Medline, and Mendeley) were searched from inception up until September 8, 2023; peer-reviewed in vitro and in vivo investigations of T. flagelliforme extracts, fractions, or isolated compounds were included. Clinical trials and non-original peer-reviewed reports were excluded.
Although T. flagelliforme shows promising activity against cancer, its efficacy as a standalone anticancer treatment remains uncertain; it appears to be better suited as complementary or combined therapy.
In vitro evidence:
- The anticancer evaluation in 30 selected studies was conducted in leukemia, lymphoma, breast, oral, cervical, lung, liver, colon, and squamous cell lines.
- Pheophorbide-containing fractions of T. flagelliforme: The antiproliferative activity was assayed using the MTT method on NCI-H23 (lung cancer) and HS578T (breast cancer) cell lines. Four pheophorbide-related compounds were identified in the most active fraction, D/F19.
- Linoleic acid-rich DCM fraction against leukemia: Seven out of 12 fractions showed significant cytotoxicity against the CEMss cell line, in which fractions DCM/F7, DCM/F11 and DCM/F12 showed exceptional activity with IC50 values of 3, 5 and 6.2 μg/mL, respectively. Further studies in non-cancerous PBLs exhibited significant selectivity of DCM/F7 compared to other fractions.
- Hexane fraction against murine leukemia cells: The hexane extract of T. flagelliforme was evaluated for cytotoxic activity against in vitro culture on P388 murine leukemia cells and showed a weak IC50 of 15 μg/mL.
- Methanolic extract demonstrated excellent anti-cancer potential and induced apoptosis in different cell lines at low concentrations.
- One study found that Typhonium divaricatum extract significantly inhibited nine human cancer cell lines, including leukemia and breast cancer.
- Several groups of phytochemicals from Typhonium were investigated for their anticancer properties, and results confirmed promising growth inhibitory effects and anticancer activities against human lung, breast, prostate, and colon cancer cells.
Overall evidence strength: All established anticancer evidence for T. flagelliforme is preclinical (in vitro cell culture and animal models). This is the first genus-level review to summarize the anticancer properties of all isolated compounds from Typhonium with confirmed chemical structures; further advanced studies are necessary to establish the detailed signaling pathways involved in the anticancer property of the compounds. No completed, peer-reviewed randomized controlled trials in humans have been identified in the indexed literature as of the 2023 systematic review's search date.
5b. Anti-Inflammatory and Anti-Allergic Activity
Evidence type: In vitro and animal; no published human clinical trials identified.
Phytochemicals from Typhonium have been reported to exhibit anti-inflammatory, antioxidant, antiviral, anti-allergic, neuroprotective, and hepatoprotective properties.
A study published in Frontiers in Pharmacology (2017) investigated anti-allergic hydroxy fatty acids from T. blumei. Phytochemical study on Typhonium blumei yielded four oxygenated fatty acids; isolated compounds were identified by spectroscopic methods along with GC-MS analysis; isolated fatty acids together with a series of saturated, unsaturated, and oxygenated fatty acids were evaluated for their anti-inflammatory and anti-allergic activities in vitro.
T. flagelliforme extracts have been reported to exhibit anti-asthmatic, anti-inflammatory, and analgesic effects.
The proliferation of T. flagelliforme plant extract-treated oral cancer cells was significantly inhibited by the downregulation of NEK-7 expression compared to LPS alone, suggesting anti-inflammatory signaling modulation.
5c. Antiviral Activity
Evidence type: In vitro molecular isolation; no animal or human trials identified.
A mannose-binding lectin gene and a mannose-binding lectin possessing antiviral activity were isolated from T. blumei (= T. divaricatum). This finding is at a molecular characterization level only; no in vivo or clinical antiviral efficacy data have been published.
5d. Hepatoprotective Activity
Evidence type: Animal model; no human clinical data identified.
A cerebroside with significant antihepatotoxic activity was isolated from the root tuber of T. flagelliforme for the first time. An additional study (Ann Clin Case Stud, 2023) examined Typhonium flagelliforme for hepatoprotective effect against thioacetamide-produced liver cirrhosis in rats. The evidence is limited to animal models.
5e. Anti-Ulcerogenic Activity
Evidence type: Animal model; no human clinical data identified.
An anti-ulcerogenic study is referenced in the primary literature: anti-ulcerogenic activity of Typhonium flagelliforme aqueous leaf extract was investigated against ethanol-induced gastric mucosal injury in rats. Evidence is preclinical.
5f. Traditional Chinese Medicine Uses of T. giganteum (Bai Fu Zi)
Evidence type: Classical historical monograph documentation; limited modern pharmacological data.
The TCM uses of Bai Fu Zi (T. giganteum) for stroke sequelae, epilepsy, and phlegm-related disorders are documented in classical Chinese materia medica and reflected in pharmacopoeial monographs. T. giganteum is a traditional Chinese medicine used as part of various formulas to treat respiratory diseases, stroke, epilepsy, and is nowadays applied in cancer treatment. These uses have not been validated in modern randomized controlled trials specific to T. giganteum as a single agent.
5g. Antioxidant Activity
Evidence type: In vitro assays; no clinical evidence.
The antioxidant activity of T. divaricatum extracts was assessed using the DPPH free radical reduction method. Antioxidant activity has been attributed to the flavonoid and polyphenol content of the plant; however, this evidence remains at the in vitro level.
6. Body Systems and Health Areas Associated with Typhonium
- Haematological/Oncological System: Leukemia cell lines (CEMss, WEHI-3, P388), lymphoma, and solid tumor cell lines (breast, lung, colon, liver, prostate, cervical, oral) have been the primary targets in laboratory research. The plant is positioned in traditional practice as a complementary cancer remedy.
- Immune and Allergic System: Anti-allergic activity via mast cell degranulation inhibition; modulation of FcεRI signaling; anti-inflammatory effects documented in vitro.
- Respiratory System: Traditional use for coughs and pulmonary ailments; T. giganteum used for respiratory diseases in TCM; anti-asthmatic effects reported in animal studies for T. flagelliforme.
- Neurological System: T. giganteum (Bai Fu Zi) classically used for stroke sequelae, epilepsy, convulsions, facial paralysis, and migraine in TCM formulas. Neuroprotective properties of Typhonium phytochemicals reported in vitro.
- Hepatic System: A cerebroside with antihepatotoxic activity has been isolated; hepatoprotective effects demonstrated in animal cirrhosis models.
- Gastrointestinal System: Anti-ulcerogenic activity in animal models of ethanol-induced gastric injury.
- Musculoskeletal System: Classical TCM use of T. giganteum for wind-cold-damp arthralgia, joint pain, and dysfunction.
- Dermatological/External Use: Traditional topical application for snake bites, bruises, swelling, and scrofula.
7. Dosage Forms and Dosages Reported in Studies
No standardized, evidence-based dosage for human use has been established through clinical trials for any Typhonium species. The following dosages are those described in the cited source materials and do not constitute recommendations.
- In vitro cytotoxicity (DCM fraction, CEMss leukemia cells): The DCM/F7 fraction at 3 μg/mL significantly arrested CEMss cells. IC50 values for fractions DCM/F7, DCM/F11, and DCM/F12 were 3, 5, and 6.2 μg/mL, respectively.
- In vitro (hexane fraction, P388 murine leukemia): The hexane extract showed a weak IC50 of 15 μg/mL.
- Traditional folk method: A common folk method involves consuming a liquid extract of the whole plant mixed with honey three times daily, with a gradual reduction of dosage based on symptom improvement.
- Oral acute toxicity (animal study): Administration of T. flagelliforme extract to rats at 2000 mg/kg produced no mortality, behavioral changes, or organ abnormalities, establishing an LD50 greater than 2000 mg/kg.
8. Safety Considerations
Calcium Oxalate Raphide Irritancy
The principal well-documented hazard of raw Typhonium plant material is the presence of calcium oxalate crystals (raphides) in the tissues. Calcium oxalate crystals isolated from T. flagelliforme rhizome showed strong irritation effects in a rabbit eye model; under the same content conditions, there was no difference in irritation between the suspensions of raw medicinal materials and pure calcium oxalate crystals; the degree of irritation showed a clear dose-dependent relationship with the concentration of calcium oxalate crystals; calcium oxalate crystals are thus the irritant component in these Araceae herbal drugs.
Many plants belonging to the Araceae family can cause irritation, including Alocasia, Arisaema, Caladium, Colocasia, Dieffenbachia, and Philodendron; they all contain calcium oxalate crystals in the form of raphides.
Mucosal and Airway Toxicity in Humans
A clinical case series published in the Indian Journal of Critical Care Medicine (2020) documented human poisoning from a related species, Typhonium trilobatum. Patients presented with a toxidrome of painful pricking sensation of the oral cavity, swelling of lips and tongue, increased salivation, drooling of saliva, upper airway angioedema, and airway compromise. The symptoms are due to the local effects of calcium oxalate crystals in the tuber. One patient had significant upper airway edema and severe respiratory distress requiring emergency endotracheal intubation.
Toxicity of Typhonium is not reported much in the literature; an emergency department physician should be aware of this tuber toxicity as it presents with airway compromise, which resolves over hours.
Processing and Detoxification
In traditional Chinese medicine, raw (unprocessed) T. giganteum (Bai Fu Zi) is considered toxic. Fresh Bai Fu Zi is toxic and should be used only externally; this herb is considered toxic, although many Chinese herbs are prepared or combined to mitigate their toxicity. Processing with alum and ginger juice is the traditional method for reducing this toxicity before internal use.
Skin and Mucous Membrane Irritation
The plant is highly irritant to skin and mucous membrane, and care should be taken during its preparation for use. The plant contains calcium oxalate crystals, which can cause irritation or poisoning if not properly prepared, and traditional uses often involve detoxification methods.
Contraindications in TCM Literature
Classical TCM sources for Bai Fu Zi (T. giganteum) describe specific contraindications: do not use during pregnancy; do not use in Yin deficient heat conditions; do not use in heat stroke caused by Liver fire.
Livestock Toxicity
Due to the presence of calcium oxalate crystals causing toxicity, T. flagelliforme is avoided as fodder for livestock, limiting its agricultural integration but preserving wild populations from grazing pressure.
Absence of Human Clinical Safety Data
No published human clinical trials have evaluated the safety profile of T. flagelliforme extract or any other Typhonium species in a controlled setting. The acute oral toxicity study in rats (LD50 >2000 mg/kg) provides a preliminary indication of low acute toxicity for processed extract in animal models, but this cannot be directly extrapolated to human safety at therapeutic doses. Drug interaction data for Typhonium preparations are not available in the indexed scientific literature.
9. Limitations of the Current Evidence Base
The body of evidence for Typhonium as a medicinal agent rests almost entirely on in vitro cell culture studies and a smaller number of animal experiments. Although T. flagelliforme shows promising activity against cancer, its efficacy as a standalone anticancer treatment remains uncertain and it appears to be better suited as complementary or combined therapy. Compounding this is the significant taxonomic complexity within the genus: several Typhonium species are often confused, making it difficult to compare findings across studies using different source material and nomenclature. No phase I, II, or III human clinical trials for any indication have been published in peer-reviewed indexed journals. Standardization of extracts, identification of bioactive markers, and elucidation of pharmacokinetic parameters in humans remain outstanding requirements before clinical use could be evaluated rigorously.
References
Go back